ERBB2 and gastric cancer: For HER2-positive advanced gastric cancer patients, the addition of trastuzumab to traditional chemotherapy in a first-line setting can obtain a median overall survival (mOS) of 13.8 months, a big step in gastric cancer treatment (6).